Gross-to-net
Rebates and discounts consume a large and growing share of list price in competitive therapeutic classes.
PHARMACEUTICALS / STRATEGY + OPERATIONS
Pharmaceutical companies discover, develop, manufacture and commercialize prescription drugs, from small molecules to biologics, selling through wholesalers, specialty pharmacies and providers. Net revenue is list price minus rebates, chargebacks and discounts to PBMs, payers and government programs, while R&D and commercial spending determine future growth.
P&L OPERATING MODEL
Select a sector and switch between the profit bridge and the underlying cost structure. The baseline is indexed to revenue so the economics remain comparable.
HOW THE BUSINESS WORKS
The revenue streams and structural traits that decide where profit is made and lost in this sector.
Rebates and discounts consume a large and growing share of list price in competitive therapeutic classes.
Revenue on a product falls sharply after loss of exclusivity, so the timing of pipeline replacement drives long-term value.
Most candidates fail in clinical development, so portfolio choices and trial execution determine the return on R&D.
Biologics and sterile injectables need validated, specialized capacity that is slow and expensive to add or move.
WHAT TO WATCH
Five numbers management should review every month, and what is changing in the sector.
Shows how much of list price is kept after rebates, chargebacks and discounts.
Shows whether the pipeline can replace products facing exclusivity loss.
Early prescription trends are the best predictor of peak sales.
Tracks manufacturing efficiency and the impact of tariffs and site changes.
Prescriptions per representative or per dollar of field spend, by territory.
WHERE THE VALUE IS
The changes that usually move the P&L most in this sector, and the service that delivers each one.
Model each contract and channel discount, and stop rebate spend that buys little additional access.
Pricing strategy & discount controlPlan launches around payer access, patient support services and field targeting from the start.
Go-to-market & channel strategyDecide which products to make in-house, onshore or keep with CMOs given tariffs and capacity.
Capacity & footprint planningScreen licensing and acquisition targets against patent-cliff gaps and integration capacity.
M&A strategy & due diligenceSECTORS IN THIS INDUSTRY
The same strategic question behaves differently by customer, product, asset, regulation, channel, and business model.
Trace sequential discounts, rebates, returns and freight to pocket contribution.
New product launch hurdleCalculate the contribution break-even while separating inventory purchasing cash from cost of sold units.
Capital investment NPVDiscount level annual cash benefits and a terminal recovery against upfront capital.